You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

platinum refractory disease

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer Trial in Orlando, Albuquerque

Recruiting
  • Platinum-resistant Ovarian Cancer
  • +6 more
  • olvimulogene nanivacirepvec
  • +3 more
  • Orlando, Florida
    AdventHealth Cancer Institute
Sep 1, 2022

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Completed
Has Results
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +8 more
  • Bevacizumab
  • Irinotecan Sucrosofate
  • Chicago, Illinois
    Northwestern University
Dec 21, 2022

Ovarian Cancer, Relapsed or Refractory, Chiauranib Trial in Shanghai (chiauranib, Placebo, Paclitaxel)

Recruiting
  • Ovarian Cancer
  • +3 more
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Mar 7, 2022

Malignant Ovarian Epithelial Tumor, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma Trial in

Recruiting
  • Malignant Ovarian Epithelial Tumor
  • +9 more
  • Akt/ERK Inhibitor ONC201
  • +2 more
  • Detroit, Michigan
    Barbara Ann Karmanos Cancer Institute
May 10, 2022

Malignant Abdominal Tumor, Malignant Pelvic Tumor, Recurrent Colon Carcinoma Trial in Rochester (Cisplatin, Cytoreductive

Recruiting
  • Malignant Abdominal Neoplasm
  • +26 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 5, 2023

Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal

Recruiting
  • Platinum-Refractory Fallopian Tube Carcinoma
  • +11 more
  • Copanlisib Hydrochloride
  • +4 more
  • Aurora, Colorado
  • +2 more
Dec 8, 2022

Squamous Cell Carcinoma of Head and Neck Trial in Italy (Nivolumab 240 MG in 24 ML Injection)

Completed
  • Squamous Cell Carcinoma of Head and Neck
  • Nivolumab 240 MG in 24 ML Injection
  • Bergamo, Italy
  • +22 more
Apr 4, 2023

Germ Cell Tumors, Testicular Tumors, Non Seminomatous Germ Cell Tumors Trial in Indianapolis, Philadelphia (Pembrolizumab)

Terminated
Has Results
  • Germ Cell Neoplasms
  • +6 more
  • Indianapolis, Indiana
  • +1 more
Jul 7, 2022

Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Chemo Trial in Beijing (A combination of anti-PD-1

Completed
  • Recurrent Cervical Carcinoma
  • +4 more
  • A combination of anti-PD-1 antibody camrelizumab and albumin-bound paclitaxel
  • Beijing, Beijing, China
    Lei Li
Mar 12, 2022

Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Chemo Trial in Beijing (Anti-PD-1 antibody camrelizumab,

Recruiting
  • Recurrent Cervical Carcinoma
  • +5 more
  • Anti-PD-1 antibody camrelizumab
  • Albumin-bound paclitaxel
  • Beijing, Beijing, China
    Lei Li
Mar 12, 2022

Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Transformed B-Cell Lymphoma Trial in Saint Louis (Mosunetuzumab,

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • +3 more
  • Saint Louis, Missouri
    Washington University School of Medicine
Jul 14, 2022

Platinum-refractory Ovarian Carcinoma, Platinum-resistant Ovarian Cancer Trial in Rochester, Helsinki (TILT-123, Pembrolizumab)

Recruiting
  • Platinum-refractory Ovarian Carcinoma
  • Platinum-resistant Ovarian Cancer
  • TILT-123
  • Pembrolizumab
  • Rochester, Minnesota
  • +1 more
Aug 12, 2022

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +8 more
  • Durvalumab
  • Tremelimumab
  • Houston, Texas
    M D Anderson Cancer Center
Jul 19, 2022

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Active, not recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +11 more
  • Aldesleukin
  • +3 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Jul 13, 2022

Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in New Haven, Baltimore (Ixabepilone,

Active, not recruiting
  • Epithelial Ovarian Cancer
  • +2 more
  • New Haven, Connecticut
  • +1 more
Jan 11, 2023

Urothelial Carcinoma Trial in Ann Arbor (Pembrolizumab, SBRT)

Terminated
Has Results
  • Urothelial Carcinoma
  • Ann Arbor, Michigan
    University of Michigan Comprehensive Cancer Center
Dec 13, 2021

Platinum-resistant Recurrent Clear Cell Ovarian Cancer Trial in Guangzhou (Niraparib, Anlotinib)

Not yet recruiting
  • Platinum-resistant Recurrent Clear Cell Ovarian Cancer
  • Guangzhou, Guangdong, China
    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Nov 21, 2021

Urothelial Carcinoma Trial in Iowa City (Avelumab, Docetaxel)

Active, not recruiting
  • Urothelial Carcinoma
  • Iowa City, Iowa
    University of Iowa Hospitals and Clinics
Oct 18, 2022

Ovarian Cancer Trial in Beijing, Jinan (Niraparib)

Recruiting
  • Ovarian Cancer
  • Beijing, China
  • +1 more
Aug 27, 2021

Platinum-Resistant Lung Small Cell Carcinoma, Platinum-Sensitive Lung Small Cell Carcinoma, Recurrent Extensive Stage Lung Small

Recruiting
  • Platinum-Resistant Lung Small Cell Carcinoma
  • +3 more
  • Durvalumab
  • +2 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 5, 2023

Keratitis, Corneal Ulcer Trial in United States (PXL Platinum 330 system + Riboflavin 0.25% TE Solution, Sham CXL + Artificial

Recruiting
  • Keratitis
  • Corneal Ulcer
  • PXL Platinum 330 system + Riboflavin 0.25% TE Solution
  • Sham CXL + Artificial Tears
  • Tampa, Florida
  • +7 more
Jul 13, 2022

Small Cell Carcinoma, NSCLC, Neuroendocrine Tumors Trial in United States (RRx-001, Cisplatin, Etoposide)

Active, not recruiting
  • Small Cell Carcinoma
  • +3 more
  • Palo Alto, California
  • +9 more
May 12, 2022

Ovarian Cancer Trial in Maywood (Decitabine, Carboplatin, Paclitaxel)

Not yet recruiting
  • Ovarian Cancer
  • Maywood, Illinois
    Loyola University Medical Center
Aug 1, 2023

Incurable Platinum Refractory Germ Cell Tumors, Tumors Trial in Indianapolis, New York, Philadelphia (ASP1650)

Completed
Has Results
  • Incurable Platinum Refractory Germ Cell Tumors
  • Tumors
  • Indianapolis, Indiana
  • +2 more
Nov 30, 2021

Steroid-refractory Acute Graft-versus-host Disease Trial (MC0518, BAT)

Not yet recruiting
  • Steroid-refractory Acute Graft-versus-host Disease
  • MC0518
  • BAT
  • (no location specified)
Oct 4, 2023